In January we noted that despite Janet Yellen’s “irrational exuberance” moment when, last summer, the Fed chair mentioned biotech as a sector where valuations looked “substantially stretched,” biotech stocks have continued their relentless ascent thanks in part to M&A deals worth 40 times sales and IPOs for pre-revenue companies.Now, with the sector still making new highs, the bubble chorus is […]
The biotech sector has the potential for outsized returns, but also extra risk not seen with larger pharmaceutical companies (and larger companies in general).Sometimes the easiest way to make money is to follow Warren Buffett’s advice and not lose it in the first place. We asked some of The Motley Fool’s biotech experts to weigh in on common mistakes investors […]
If you follow me on Twitter you will have noticed my latest tweet on what to expect during uptrends and downtrends:This is my 17th year trading the markets. The above statement is the essence of what I am experiencing on a daily basis. In order to get exposure to potential super winners you have to identify the right pond to […]
View this article –
OREX – Orexigen Therapeutics – Getting out at the top
See which stocks are being affected by Social Media
[…]
Source: Neuralstem.I haven’t bought these three little-known biotech stocks (yet), but I am watching them closely because I think each of them could have catalysts soon that could move their shares this year. All three are small-market-cap companies that come with risks that are common in this highly speculative pop-and-drop industry, but for investors willing to take a risk, these […]
Gilead, without a doubt, has proven itself to be a leader in the biotechnology industry. The stock has had an extremely bullish pattern over the last four years, growing over 400% in stock price since March 2011. However, over the last 6 months, the stock has seen a loss of about 5%.In fact, there has been a considerable amount of […]
See original:
Forget Gilead Sciences (GILD), Buy These Biotech Stocks Instead – Stocks in the News
[…]
Lim: Nasdaq 5,000 Not Different This TimeMarch 3, 2015“Tech is 47% of the index … [A]t an average P/E of 21.5, the Nasdaq is still considerably more expensive than the Dow Jones industrial average, the S&P 500, European stocks, emerging market stocks, and the list goes on and on. …“[T]he Nasdaq Biotech index now trades at P/E of around 50. […]
Capitalist Bull: Price Action Impressive Volume Not So Much
PagesHome
Leading Growth Stocks Analysis
Short Trading Ideas
SERVICES
Newsletter Sign Up
Interviews
About Us
Disclaimer
Price Action Impressive Volume Not So MuchMarket price action has been impressive by any respect. Despite persistent bad news from around the world, and numerous internal red flags, the NYSE advance decline line continues to trade near new highs, and the market marches higher […]
Read More –
The spinoff frenzy that started with tiny Noor Energy
See which stocks are being affected by Social Media
[…]
